About Meningitis
Meningitis (meningococcal diseases) is characterized by inflammation of the protective lining (meninges) present around the brain and spinal cord. It can be classified into infectious and non-infectious meningitis. Based on the types of organism, infectious meningitis is sub-divided into bacterial meningitis, viral meningitis, fungal meningitis, and parasitic meningitis. Bacterial meningitis occurs due to bacterial species such as hemophilus influenzae, listeria monocytogenes, neisseria meningitidis, and streptococcus pneumoniae.
Technavio’s analysts forecast the global meningococcal vaccines market to grow at a CAGR of 13.07% during the period 2016-2020.
Covered in this report
The report covers the present scenario and the growth prospects of the global meningococcal vaccines market for 2016-2020. To calculate the market size, the report considers the the report considers the revenue generated from the sales of vaccines used to prevent meningococcal infections.
The market is divided into the following segments based on geography:
• Americas
• APAC
• EMEA
Technavio's report, Global Meningococcal Vaccines Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
Key vendors
• GSK
• Pfizer
• Sanofi
Other prominent vendors
• Beijing Minhai Biotechnology
• Bio Med
• Hualan Biological Engineering
• Imunoloski Zavod
• JN International Medical
• Nuron Biotech
• Serum Institute of India
• Vacunas Finlay SA
• Merck
• GlycoVaxyn
• Baxter
Market driver
• Designated as a traveller’s vaccine
• For a full, detailed list, view our report
Market challenge
• High cost associated with vaccine development
• For a full, detailed list, view our report
Market trend
• Increase in strategic alliances and M&A
• For a full, detailed list, view our report
Key questions answered in this report
• What will the market size be in 2020 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?
You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.
PART 01: Executive summary
• Highlights
PART 02: Scope of the report
• Market overview
• Top-vendor offerings
PART 03: Market research methodology
• Research methodology
• Economic indicators
PART 04: Introduction
• Key market highlights
• Key buying criteria
PART 05: Overview of vaccines
• Understanding Meningococcal disease
• Causes of meningococcal diseases
• Signs and symptoms
• Epidemiology
• Vaccine approval process
PART 06: Market landscape
• Market overview
• Market size and forecast
• Five forces analysis
PART 07: Market segmentation by composition
• Mono vaccines
• Combination vaccines
PART 08: Geographical segmentation
• Global meningococcal vaccines market by geographical segmentation 2015-2020
• Meningococcal vaccines market in Americas
• Meningococcal vaccines market in US
• Meningococcal vaccines market in the Brazil
• Meningococcal vaccines market in EMEA
• Meningococcal vaccines market in Europe
• Meningococcal vaccines market in APAC
• Meningococcal vaccines market in Australia
PART 09: Market drivers
• Increase in awareness about vaccination and immunization programs
• Designated as a traveler's vaccine
• Inclusion in national immunization schedule
• Threat of bioterrorism
• Additional age group approval
PART 10: Impact of drivers
PART 11: Market challenges
• Vaccine storage and handling issues
• High cost associated with vaccine development
• Stringent regulations
• Emergence of local players
• Adverse effects
PART 12: Impact of drivers and challenges
PART 13: Market trends
• Availability of combination vaccines
• Increase in strategic alliances and M&A
• Focus on emerging markets
• Public-private initiatives
PART 14: Vendor landscape
• Competitive scenario
• Market share analysis 2015
• Sanofi
• GlaxoSmithKline (GSK)
• Pfizer
• Other prominent vendors
PART 15: Appendix
• List of abbreviations
PART 16: Explore Technavio
?
List of Exhibits
Exhibit 01: Product offerings
Exhibit 02: Key buying criteria for meningococcal vaccines
Exhibit 03: Distribution of meningococcal bacterial strains
Exhibit 04: Distribution of meningococcal bacterial strains in US
Exhibit 05: Distribution of meningococcal bacterial strains UK
Exhibit 06: Different type of bacterial causes of meningitis
Exhibit 07: Requirements for a BLA submission
Exhibit 08: Different types of development necessary to reach vaccine licensing stage
Exhibit 09: Vaccine development process over a period of up to 15 years at a cost of up to $1 billion
Exhibit 10: Regulatory testing of licensed vaccines
Exhibit 11: Pediatric/VFC meningococcal vaccine price list 2015
Exhibit 12: Price of adult meningococcal vaccine 2015
Exhibit 13: Global meningococcal vaccines market 2015-2020 ($ billions)
Exhibit 14: Five forces analysis
Exhibit 15: Global meningococcal vaccines market segmentation by composition
Exhibit 16: Global meningococcal vaccines market by composition 2015
Exhibit 17: Global meningococcal vaccines market by geography 2015
Exhibit 18: Global meningococcal vaccines market revenue by geography 2015-2020 ($ millions)
Exhibit 19: Percentage share of meningococcal vaccines market by geography 2015-2020
Exhibit 20: Global meningococcal vaccines market: YoY revenue and growth based on geography 2015-2020 ($ millions)
Exhibit 21: Meningococcal vaccines market in Americas 2015-2020 ($ billions)
Exhibit 22: Meningococcal vaccines market in America by country 2015
Exhibit 23: Meningococcal vaccines market in US 2015-2020 ($ billions)
Exhibit 24: Meningococcal vaccines market in Brazil 2015-2020 ($ millions)
Exhibit 25: Meningococcal vaccines market in EMEA 2015-2020 ($ millions)
Exhibit 26: Meningococcal vaccines market in EMEA by country 2015
Exhibit 27: Meningococcal vaccines market in Europe 2015-2020 ($ millions)
Exhibit 28: Meningococcal vaccines market in APAC 2015-2020 ($ millions)
Exhibit 29: Meningococcal vaccines market in APAC by country 2015
Exhibit 30: Meningococcal vaccines market in Australia 2015-2020 ($ millions)
Exhibit 31: Impact of drivers
Exhibit 32: A typical cold chain process
Exhibit 33: Impact of drivers and challenges
Exhibit 34: Overview of major vaccine related acquisitions (2005-2012)
Exhibit 35: Market share analysis of global meningococcal vaccines market 2015
Exhibit 36: Sanofi: YoY revenue growth of Meningitis/Pneumonia vaccines 2013-2015 ($ millions)
Exhibit 37: Geographical segmentation of meningitis/pneumococcal vaccines by revenue 2015
Exhibit 38: Sanofi: YoY revenue growth of Menactra 2013-2015 ($ millions)
Exhibit 39: Geographical segmentation of Menomune by revenue 2015
Exhibit 40: Key takeaways
Exhibit 41: Geographical segmentation of Bexsero by revenue 2015
Exhibit 42: Geographical segmentation of Menveo by revenue 2015
Exhibit 43: Key takeaways
Exhibit 44: Key takeaways
